Quidel vs BioLife Solutions: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Quidel Corporation (QDEL)

Q3 202623 Jul – 17 Aug 2026

▼3▲1

QuidelOrtho slashes 2026 outlook on China and respiratory weakness

2026 guidance slashed, shares plunge QuidelOrtho beat second-quarter estimates but cut full-year 2026 revenue guidance to $2.52-$2.60 billion from $2.70-$2.75 billion, and earnings guidance to 65-90 cents from $1.80-$2.00. Shares fell about 25% as investors absorbed the much weaker outlook.
The guidance cut is the single biggest new force pushing QDEL down this period.
China pricing rules and weak respiratory season China's draft in-vitro diagnostics pricing guidelines expanded to six provinces, causing distributors to cut inventories faster than expected; China revenue fell 18.7%. Management also now assumes a weaker-than-average respiratory season, removing a hoped-for rebound.
These are the specific demand problems management blamed for the guidance cut.
Analyst fair value and targets cut Simply Wall St cut its fair value estimate to $12 from $20.50, citing much lower growth assumptions. Analyst targets now cluster between $12 and $18, with JPMorgan at $12 (Underweight) and Citi at $18 (Neutral), showing deep disagreement on the stock's path.
It shows how professional valuations were reset lower after the guidance cut.
Possible point-of-care sale could cut debt QuidelOrtho is reportedly looking to sell its point-of-care division for about $1.5 billion, which would undo the 2022 merger and leave a steadier diagnostics business. One large holder sees the stock worth roughly $100 per share if the sale happens and debt falls.
It is the main potential upside counterweight to the weak guidance.

August 202623 Jul – 17 Aug 2026

▼3▲1

QuidelOrtho slashes 2026 outlook on China and respiratory weakness

2026 guidance slashed, shares plunge QuidelOrtho beat second-quarter estimates but cut full-year 2026 revenue guidance to $2.52-$2.60 billion from $2.70-$2.75 billion, and earnings guidance to 65-90 cents from $1.80-$2.00. Shares fell about 25% as investors absorbed the much weaker outlook.
The guidance cut is the single biggest new force pushing QDEL down this period.
China pricing rules and weak respiratory season China's draft in-vitro diagnostics pricing guidelines expanded to six provinces, causing distributors to cut inventories faster than expected; China revenue fell 18.7%. Management also now assumes a weaker-than-average respiratory season, removing a hoped-for rebound.
These are the specific demand problems management blamed for the guidance cut.
Analyst fair value and targets cut Simply Wall St cut its fair value estimate to $12 from $20.50, citing much lower growth assumptions. Analyst targets now cluster between $12 and $18, with JPMorgan at $12 (Underweight) and Citi at $18 (Neutral), showing deep disagreement on the stock's path.
It shows how professional valuations were reset lower after the guidance cut.
Possible point-of-care sale could cut debt QuidelOrtho is reportedly looking to sell its point-of-care division for about $1.5 billion, which would undo the 2022 merger and leave a steadier diagnostics business. One large holder sees the stock worth roughly $100 per share if the sale happens and debt falls.
It is the main potential upside counterweight to the weak guidance.

Latest23 Jul – 17 Aug 2026

▼3▲1

QuidelOrtho slashes 2026 outlook on China and respiratory weakness

2026 guidance slashed, shares plunge QuidelOrtho beat second-quarter estimates but cut full-year 2026 revenue guidance to $2.52-$2.60 billion from $2.70-$2.75 billion, and earnings guidance to 65-90 cents from $1.80-$2.00. Shares fell about 25% as investors absorbed the much weaker outlook.
The guidance cut is the single biggest new force pushing QDEL down this period.
China pricing rules and weak respiratory season China's draft in-vitro diagnostics pricing guidelines expanded to six provinces, causing distributors to cut inventories faster than expected; China revenue fell 18.7%. Management also now assumes a weaker-than-average respiratory season, removing a hoped-for rebound.
These are the specific demand problems management blamed for the guidance cut.
Analyst fair value and targets cut Simply Wall St cut its fair value estimate to $12 from $20.50, citing much lower growth assumptions. Analyst targets now cluster between $12 and $18, with JPMorgan at $12 (Underweight) and Citi at $18 (Neutral), showing deep disagreement on the stock's path.
It shows how professional valuations were reset lower after the guidance cut.
Possible point-of-care sale could cut debt QuidelOrtho is reportedly looking to sell its point-of-care division for about $1.5 billion, which would undo the 2022 merger and leave a steadier diagnostics business. One large holder sees the stock worth roughly $100 per share if the sale happens and debt falls.
It is the main potential upside counterweight to the weak guidance.

BioLife Solutions Inc (BLFS)

Q3 202622 Jul – 5 Oct 2026

▲2▼2

Repligen's $1.5B buyout locks BLFS to deal terms, not its own news

Repligen agrees to buy BioLife for $1.5 billion Repligen will pay $31 a share — $11.25 cash plus Repligen stock — a 24% premium to BioLife's recent average price. That buyout price now acts like a magnet for the stock: it trades near the deal value, and shareholders get cash plus Repligen shares when it closes.
The acquisition is the single force now setting BLFS's price.
Q2 beat shows the underlying business was healthy BioLife earned $0.04 a share versus an expected small loss, with revenue of $28.5 million, up about 21% from a year earlier and above forecasts — its fourth straight beat. Strong results support the deal price and make the buyer's case easier.
Shows the company's own performance still matters as a backstop to the deal.
Law firm probes whether the sale price is fair Investor-rights firm Halper Sadeh is investigating whether BioLife's board got shareholders a fair deal in the Repligen sale. Such reviews are common and often lead nowhere, but they can delay closing or pressure the buyer to raise its offer.
A real counterweight that could change deal terms or timing.
Removed from the S&P SmallCap 600 index BioLife is being dropped from the S&P SmallCap 600 and replaced by Freshworks, because it is being acquired. Index funds that tracked it must sell, but with the buyout nearly done, this mostly reflects the deal closing rather than new weakness.
Explains the forced selling around the deal's completion.

August 202622 Jul – 5 Oct 2026

▲2▼2

Repligen's $1.5B buyout locks BLFS to deal terms, not its own news

Repligen agrees to buy BioLife for $1.5 billion Repligen will pay $31 a share — $11.25 cash plus Repligen stock — a 24% premium to BioLife's recent average price. That buyout price now acts like a magnet for the stock: it trades near the deal value, and shareholders get cash plus Repligen shares when it closes.
The acquisition is the single force now setting BLFS's price.
Q2 beat shows the underlying business was healthy BioLife earned $0.04 a share versus an expected small loss, with revenue of $28.5 million, up about 21% from a year earlier and above forecasts — its fourth straight beat. Strong results support the deal price and make the buyer's case easier.
Shows the company's own performance still matters as a backstop to the deal.
Law firm probes whether the sale price is fair Investor-rights firm Halper Sadeh is investigating whether BioLife's board got shareholders a fair deal in the Repligen sale. Such reviews are common and often lead nowhere, but they can delay closing or pressure the buyer to raise its offer.
A real counterweight that could change deal terms or timing.
Removed from the S&P SmallCap 600 index BioLife is being dropped from the S&P SmallCap 600 and replaced by Freshworks, because it is being acquired. Index funds that tracked it must sell, but with the buyout nearly done, this mostly reflects the deal closing rather than new weakness.
Explains the forced selling around the deal's completion.

Latest22 Jul – 5 Oct 2026

▲2▼2

Repligen's $1.5B buyout locks BLFS to deal terms, not its own news

Repligen agrees to buy BioLife for $1.5 billion Repligen will pay $31 a share — $11.25 cash plus Repligen stock — a 24% premium to BioLife's recent average price. That buyout price now acts like a magnet for the stock: it trades near the deal value, and shareholders get cash plus Repligen shares when it closes.
The acquisition is the single force now setting BLFS's price.
Q2 beat shows the underlying business was healthy BioLife earned $0.04 a share versus an expected small loss, with revenue of $28.5 million, up about 21% from a year earlier and above forecasts — its fourth straight beat. Strong results support the deal price and make the buyer's case easier.
Shows the company's own performance still matters as a backstop to the deal.
Law firm probes whether the sale price is fair Investor-rights firm Halper Sadeh is investigating whether BioLife's board got shareholders a fair deal in the Repligen sale. Such reviews are common and often lead nowhere, but they can delay closing or pressure the buyer to raise its offer.
A real counterweight that could change deal terms or timing.
Removed from the S&P SmallCap 600 index BioLife is being dropped from the S&P SmallCap 600 and replaced by Freshworks, because it is being acquired. Index funds that tracked it must sell, but with the buyout nearly done, this mostly reflects the deal closing rather than new weakness.
Explains the forced selling around the deal's completion.